<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454544</url>
  </required_header>
  <id_info>
    <org_study_id>MT-06</org_study_id>
    <secondary_id>2011-002277-38</secondary_id>
    <nct_id>NCT01454544</nct_id>
  </id_info>
  <brief_title>A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet</brief_title>
  <acronym>MT-06</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this trial is to evaluate the efficacy of the ALK house dust mite tablet
      given once daily compared to a placebo tablet in the treatment of house dut mite allergic
      rhinits.

      Additionally the secondary objective of the trial is to evaluate the safety and tolarability
      of the ALK house dust mite tablet.

      Immunotherapy has been shown to provide therapeutic benefits to subjects with house dust mite
      induced allergy. This trial is planned to investigate if clinically relevant improvements in
      rhinitis symptoms and with less use of symptomatic medication can be obtained in subjects
      with a history of poor didease control despite of use of symptomatic medications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of allergy symptoms and use of symptomatic medication</measure>
    <time_frame>1 year with treatment</time_frame>
    <description>Comparing the daily recording of symptoms and use of symptomatic medication during the last period of the trial between the actively treated patients and the placebo treated.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">992</enrollment>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>ALK house dust mite tablet 6 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK house dust mite tablet 12 DU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIT Tablet</intervention_name>
    <description>1 tablet per day in 12 months</description>
    <arm_group_label>ALK house dust mite tablet 6 DU</arm_group_label>
    <arm_group_label>ALK house dust mite tablet 12 DU</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A history of house dust mite allergy

          -  Use of symptomatice medication for treatment of house dust mite allergy

          -  Positive skin prick test to mites

          -  Positive specific IgE

        Exclusion Criteria:

          -  History of uncontrolled asthma

          -  Overlapping symptomatice allergies

          -  Previous treatment with immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Respiratory Diseases, Lapeyronie Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26788764</url>
    <description>SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

